Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 2012 Sep;167(2):353–355. doi: 10.1111/j.1476-5381.2012.01963.x

What would 5-HT do? Regional diversity of 5-HT1 receptor modulation of primary afferent neurotransmission

Mark Connor 1
PMCID: PMC3481042  PMID: 22462412

Abstract

5-HT (serotonin) is a significant modulator of sensory input to the CNS, but the only analgesics that selectively target G-protein-coupled 5-HT receptors are highly specific for treatment of headache. Two recent papers in BJP shed light on this puzzling situation by showing that primary afferent neurotransmission to the superficial layers of the spinal and trigeminal dorsal is inhibited by different subtypes of the 5-HT1 receptor – 5-HT1B(and 1D) in the trigeminal dorsal horn and 5-HT1A in the spinal dorsal horn. The inputs being studied probably include nociceptive afferents, and the similarities of the methods employed in the two studies minimize the possibility that the different findings are an experimental artefact. Rather, the findings raise interesting questions about the possible anatomical or functional basis for the apparent regional selectivity of 5-HT1 receptor actions, and whether these differences could be exploited for therapy. The results also emphasize the relative lack of information we have about the molecular details of the pro- or anti-nociceptive actions of 5-HT itself on primary afferent neurotransmission.

LINKED ARTICLE

This article is a commentary on Choi et al., pp. 356–367 of this issue. To view this paper visit http://dx.doi.org/10.1111/j.1476-5381.2012.01964.x

Keywords: migraine, triptans, nociception, EPSC


5-HT (serotonin) is a significant modulator of sensory input to the CNS, with neurons in the raphe nuclei providing dense 5-hydroxytryptaminergic projections to all laminae of the spinal cord and trigeminal dorsal horn (reviewed in Millan, 2002). Drugs that mimic the actions of 5-HT at a subset of 5-HT receptors relieve migraine headache in many people (Ferrari et al., 2001), but they are not effective inhibitors of non-headache-related pain, and there is little evidence that agents that selectively target other 5-HT receptors or modulate endogenous 5-HT levels are effective analgesics in people. 5-HT can act on many types of neuron involved in sensory processing in the spinal cord via multiple receptor types located on the intrinsic spinal cord neurons and their inputs (Millan, 2002). Two recent studies in BJP demonstrate distinct differences between the types of 5-HT1 receptor (Alexander et al., 2011) potentially mediating inhibitory actions of 5-HT on spinal and trigeminal primary afferent neurotransmission in rat (Choi et al., 2012; Jeong et al., 2012). Their results highlight that even within contiguous regions of the CNS with the same function, the distinct functional profile of closely related receptors provides a tantalizing opportunity for selective pharmacological targeting of different pain states.

In this issue of the journal, Choi and colleagues report that activation of 5-HT1B (and 5-HT1D) receptors inhibit primary afferent-evoked synaptic inputs to the trigeminal dorsal horn, while Jeong et al. (2012) showed that 5-HT1A but not 5-HT1B, 5-HT1D or 5-HT1F receptor activation inhibited primary afferent transmission in the lumbar dorsal horn. Both studies used whole cell patch clamp techniques to record glutamatergic excitatory postsynaptic currents (EPSCs) from dorsal horn lamina II neurons in rats of a similar age and the same strain. Lamina II neurons receive significant input from nociceptive C- and Aδ fibre primary afferents and inhibition of EPSCs in these cells is reasonably considered a proxy for potential anti-nociceptive effects. The findings in the trigeminal dorsal horn are consistent with a large body of data in several species showing that 5-HT1B, 5-HT1D and/or 5HT1F receptors inhibit activation of the second order neurons in the trigeminal dorsal horn by nociceptive inputs in vivo, but there is little correlative behavioural data from awake animals, presumably because of the difficulty of applying drugs to the brainstem in these conditions. In contrast, Jeong et al. (2012) showed that intrathecal administration of 5-HT1 receptor agonists inhibited thermal and mechanical nociception in a manner entirely consistent with their in vitro findings – that is, only 5-HT1A receptor activation was effective.

While perhaps not surprising in the context of past findings, these studies highlight some interesting questions. Perhaps foremost is how the apparent regional selectivity in 5-HT1 receptor function arises. There is good anatomical evidence for the expression of each of the 5-HT1 receptors in dorsal root and trigeminal ganglia (e.g. Potrebic et al., 2003; Classey et al., 2010), so why are all the receptors not active in modulating primary afferent neurotransmission? There is no easy answer. It is possible that the room temperature recording conditions in the study of Choi et al. (2012) preferentially limited the activity of some 5-HT1 receptor subtypes, and it is not clear that this study (and previous work in the same region, Jennings et al., 2004) was geared to pick up the 5-HT1A activity of sumatriptan (in lieu of using specific 5-HT1A ligands). More intriguingly, it is possible that different types of 5-HT1 receptor are on neurons that project to distinct laminae of the trigeminal or spinal dorsal horn. This seems unlikely for 5-HT1D receptors, as receptor immunoreactivity is concentrated in the superficial laminae of both trigeminal and spinal dorsal horn (Potrebic et al., 2003), but the situation is much less clear-cut for other 5-HT1 receptors. A more complex 5-HT receptor pharmacology has been reported for dorsal horn neurons in laminae III to VI in very young rats (Garraway and Hochman, 2001), but this appeared to change even over the first 2 weeks of life, raising the possibility that plasticity of receptor expression makes comparisons between the 2- to 3-week-old animals used for electrophysiology and the young adult animals used in studies of nociception problematic.

While uncertainties may exist over the exact distribution of 5-HT1A/B/F receptors, there is clear evidence that 5-HT1D receptors are found on afferents projecting to both lamina II neurons in lumbar and trigeminal dorsal horn, yet equally compelling evidence indicates that 5-HT1D receptors only inhibit primary afferent neurotransmission in the trigeminal dorsal horn. In both locations, 5-HT1D receptors have been primarily localized to presynaptic dense core vesicles, structures whose contents are usually only mobilized to the membrane by relatively intense stimulation (Potrebic et al., 2003). Recent data show that 5-HT1D receptor activation can inhibit nociception associated with inflammation of spinally innervated structures, consistent with receptors being expressed on the surface of sensory neuron terminals undergoing strong stimulation (Nikai et al., 2008; Vera-Portocarrero et al., 2008). The proposition that inflammation induces trafficking of 5-HT1D receptors has not been tested using recordings of primary afferent EPSCs from dorsal horn neurons, but such experiments could provide mechanistic support for the prospect of pharmacological targeting of receptors that are only active when nociceptors are strongly activated – a very appealing idea. The activity of 5-HT1D agonists in the naïve trigeminal system could reflect the presence of a small population of surface localized receptors not available in spinal cord afferents, different stimulation conditions required to mobilize intracellular receptors in the two afferent populations or signal transduction pathways mediating inhibition of neurotransmitter release that are only recruited by noxious stimulation in the dorsal horn. Distinguishing between these possibilities is likely to be a worthwhile exercise.

Of course, the major unanswered physiological question in both studies is what would 5-HT do? Previous work has indicated that 5-HT can both potentiate and inhibit primary afferent neurotransmission (e.g. Hori et al., 1996; Garraway and Hochman, 2001), and given that most subtypes of 5-HT receptor are present in sensory ganglia, 5-HT potentially has both pro- and anti-nociceptive effects through modulation of primary afferent neurotransmission, consistent with the findings that 5-hydroxytryptaminergic neurons projecting to the spinal cord can be parts of distinct descending pathways that facilitate or inhibit noxious sensory information (Millan, 2002). The studies of Jeong et al. (2012) and Choi et al. (2012) demonstrate a clear difference in the potential mechanisms of 5-HT modulation of noxious information flow from the head and body, careful investigation of the role of other 5-HT receptors in modulating primary afferent inputs is likely to reveal more interesting and potentially therapeutically exploitable differences.

Acknowledgments

MC is supported by the NHMRC of Australia.

Conflict of Interest statement

MC currently collaborates with the authors of one the studies that are the subject of this commentary (H-Y Jeong, CW Vaughan) on unrelated work.

References

  1. Alexander SPH, Mathie A, Peters JA. Guide to receptor and channels (GRAC), 5th edn. Br J Pharmacol. 2011;164(Suppl. 1):S1–S324. doi: 10.1111/j.1476-5381.2011.01649_1.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Choi I-S, Cho J-H, An C-H, Jung J-K, Hur Y-K, Choi C-S, et al. 5-HT1B receptors inhibit glutamate release from primary afferent terminals in rat medullary dorsal horn neurons. Br J Pharmacol. 2012;167:356–367. doi: 10.1111/j.1476-5381.2012.01964.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Classey JD, Bartsch T, Goadsby PJ. Distribution of 5-HT1B, 5-HT1D and 5-HT1F receptor expression in rat trigeminal and dorsal root ganglia neurons: relevance to the selective anti-migraine effect of triptans. Brain Res. 2010;1361:76–85. doi: 10.1016/j.brainres.2010.09.004. [DOI] [PubMed] [Google Scholar]
  4. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta analysis of 53 trials. Lancet. 2001;358:1668–1675. doi: 10.1016/S0140-6736(01)06711-3. [DOI] [PubMed] [Google Scholar]
  5. Garraway SM, Hochman S. Pharmacological characterization of serotonin receptor subtypes modulating primary afferent input to deep dorsal horn neurons in the neonatal rat. Br J Pharmacol. 2001;132:1789–1798. doi: 10.1038/sj.bjp.0703983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hori Y, Endo K, Takahashi T. Long-lasting synaptic facilitation induced by serotonin in superficial dorsal horn neurones of the rat spinal cord. J Physiol. 1996;492:867–876. doi: 10.1113/jphysiol.1996.sp021352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jennings EA, Ryan RM, Christie MJ. Effects of sumatriptan on rat medullary dorsal horn neurons. Pain. 2004;111:30–37. doi: 10.1016/j.pain.2004.05.018. [DOI] [PubMed] [Google Scholar]
  8. Jeong H-Y, Mitchell VA, Vaughan CW. Role of 5-HT1 receptor subtypes in the modulation of pain and synaptic transmission in rat superficial dorsal horn. Br J Pharmacol. 2012;165:1956–1965. doi: 10.1111/j.1476-5381.2011.01685.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66:355–474. doi: 10.1016/s0301-0082(02)00009-6. [DOI] [PubMed] [Google Scholar]
  10. Nikai T, Basbaum AI, Ahn AH. Profound reduction of somatic and visceral pain in mice by intrathecal administration of the anti-migraine drug, sumatriptan. Pain. 2008;139:533–540. doi: 10.1016/j.pain.2008.06.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Potrebic S, Ahn A, Skinner K, Fields HL, Basbaum AI. Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans. J Neurosci. 2003;23:10988–10997. doi: 10.1523/JNEUROSCI.23-34-10988.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Vera-Portocarrero LP, Ossipov MH, King T, Porreca F. Reversal of inflammatory and non-inflammatory visceral pain by central or peripheral actions of sumatriptan. Gastroenterology. 2008;135:1369–1378. doi: 10.1053/j.gastro.2008.06.085. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES